"Jose Jeronimo, MD, is a gynecologic oncologist and currently serves as Chief Technical Officer for the Global Coalition against Cervical Cancer (GC3). He is also advisor for the Union for International Cancer Control (UICC), Geneva, in the evaluation, planning and implementation of cancer control plans in cities with more than one million inhabitants, including Cali (Colombia), Asuncion (Paraguay), Kumasi (Ghana) and Yangon (Myanmar). In the past, Dr. Jeronimo was a staff scientist for the Division of Cancer Epidemiology and Genetics at the US National Cancer Institute (NCI/NIH). Later, he moved to PATH, Seattle, where he led several multi-national projects focused on the development, validation and implementation of new technologies for cancer diagnosis and treatment.
"Dr. Jeronimo is recognized as a global leader in cancer. He is member of the board of directors of the International Papilloma Virus Society and the American Society for Colposcopy and Cervical Pathology (ASCCP), editor of the Papilloma Virus Research Journal, member of the editorial board of the journal of the American Society for Colposcopy and Cervical Pathology (ASCCP), and advisor for the cervical cancer screening Lab to Scale Program at Duke University." 
A 2018 article notes "Dr. Jeronimo is a consultant for Merck, a manufacturer of HPV vaccines, and was a consultant for Qiagen Inc, manufacturer of HPV diagnostic tests, in 2017. He was co‐owner and Deputy Manager of Onco Prev International, a Peruvian company, from 2012 through March 2017. Onco Prev offers cervical cancer screening services and in 2016 also began positioning for distribution of medical devices including colposcopes and the Liger thermocoagulator. Onco Prev International did not commercialize any medical instrument during the time Dr. Jeronimo was part of the company. " 
Resources and articles
- globalhealth.duke Jose Jeronimo, accessed April 30, 2020.